Journal of Antimicrobial Chemotherapy (2000) 45, 813-818
© 2000 The British Society for Antimicrobial Chemotherapy
Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders
CBD Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
Melioidosis and glanders are caused by the closely related species Burkholderia pseudomallei and Burkholderia mallei, respectively. Whereas melioidosis is a significant cause of morbidity in south-east Asia, glanders is extremely rare. The efficacies of ciprofloxacin and doxycycline were assessed against a strain of B. pseudomallei and a strain of B. mallei which were susceptible to both antimicrobials in vitro. Porton outbred mice and Syrian hamsters were given 40 mg/kg of either doxycycline or ciprofloxacin twice daily by sc injection according to one of three regimens: dosing starting 48 h before challenge and continuing for 5 days postchallenge; 5 days' therapy starting immediately after challenge; 5 days' therapy starting 24 h after challenge. Mice were challenged ip with B. pseudomallei 4845 and hamsters were challenged ip with B. mallei 23344. Antimicrobial efficacy was determined by the shift in the median lethal dose (MLD). Ciprofloxacin prophylaxis and immediate therapy both raised the MLD of B. pseudomallei to 4 x 106 cfu from 19 cfu in untreated animals, but therapeutic ciprofloxacin only raised the MLD to 180 cfu. The results for doxycycline were similar. Ciprofloxacin prophylaxis raised the MLD of B. mallei 23344 to 4.6 x 105 cfu compared with 4 cfu in untreated controls. Immediate therapy raised the MLD to 7.0 x 104 cfu and therapy raised the MLD to 1.6 x 103 cfu. All regimens of doxycycline protected hamsters against challenges of up to 2 x 107 cfu. Despite using a susceptible strain of B. pseudomallei, neither antimicrobial was effective when used therapeutically. The timely administration of either antimicrobial, however, was effective in preventing symptomatic infection. Doxycycline was the superior of the two antimicrobials against experimental glanders although relapse did occur in treated animals approximately 4–5 weeks after challenge.
* Corresponding author. Tel: +44-1980-613-438; Fax: +44-1980-613-097; E-mail: drprussell{at}hotmail.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Sivalingam, S. H. Sim, L. C. W. Jasper, D. Wang, Y. Liu, and E. E. Ooi Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole J. Antimicrob. Chemother., March 1, 2008; 61(3): 674 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Sivalingam, S. H. Sim, L. T. Aw, and E. E. Ooi Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore J. Antimicrob. Chemother., November 1, 2006; 58(5): 1102 - 1103. [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. J. Inglis and J.-L. Sagripanti Environmental Factors That Affect the Survival and Persistence of Burkholderia pseudomallei Appl. Envir. Microbiol., November 1, 2006; 72(11): 6865 - 6875. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Cheng and B. J. Currie Melioidosis: Epidemiology, Pathophysiology, and Management Clin. Microbiol. Rev., April 1, 2005; 18(2): 383 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steward, T. Piercy, M. S. Lever, M. Nelson, A. J. H. Simpson, and T. J. G. Brooks Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection J. Antimicrob. Chemother., April 1, 2005; 55(4): 523 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Thibault, E. Hernandez, D. R. Vidal, M. Girardet, and J.-D. Cavallo Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents J. Antimicrob. Chemother., December 1, 2004; 54(6): 1134 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steward, M. S. Lever, A. J. H. Simpson, A. M. Sefton, and T. J. G. Brooks Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones J. Antimicrob. Chemother., July 1, 2004; 54(1): 95 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lever, M. Nelson, P. I. Ireland, A. J. Stagg, R. J. Beedham, G. A. Hall, G. Knight, and R. W. Titball Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse J. Med. Microbiol., December 1, 2003; 52(12): 1109 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.M. JONES, J.F. ELLIS, P. RUSSELL, K.F. GRIFFIN, and P.C. F. OYSTON Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins J. Med. Microbiol., December 1, 2002; 51(12): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. White Chemical and biological weapons. Implications for anaesthesia and intensive care{dagger} Br. J. Anaesth., August 1, 2002; 89(2): 306 - 324. [Abstract] [Full Text] [PDF]
|
|